Alterity Therapeutics (ASX: ATH), a biotech firm focused on neurodegenerative disease treatments, has successfully raised AU$3.25 million through a placement of ordinary shares. This funding ensures financial support until the primary Phase 2 trial's data readout for their ATH434-201 study in Multiple System Atrophy (MSA). CEO David Stamler, M.D., expressed gratitude for investor support and outlined upcoming milestones, including reporting preliminary data from the Biomarker study in early 2024 and completing the 201 study by November 2024.
The placement, priced at AU$0.0038 per share, includes free attaching options for investors. Proceeds will primarily fund ongoing Phase 2 trials for MSA and potentially a Phase 3 trial, as well as research in Parkinson's Disease and general operations. Alterity aims to revolutionize neurodegenerative disease treatment with its lead asset, ATH434, currently in two Phase 2 MSA trials
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
